Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04478097
Other study ID # A70_09BE2005
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date July 14, 2020
Est. completion date January 1, 2021

Study information

Verified date July 2020
Source Chong Kun Dang Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, open, single-dose, 3 period partial replicated crossover-design study to investigate the pharmacokinetic profiles and safety of CKD-333 in healthy volunteers.


Description:

To healthy subjects of fifty-one (51), following treatments are administered dosing in each period and wash-out period is a minimum of 14 days.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 51
Est. completion date January 1, 2021
Est. primary completion date November 5, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 54 Years
Eligibility Inclusion Criteria:

1. Healthy adults over the age of 19 years and under the age of 55 years at the time of screening

2. Individuals who had 17.5 kg/m2 = Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight = 55 kg, women's total body weight = 45 kg

* BMI = Weight(kg)/ Height(m)2

3. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years

4. Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/bacterial, etc.) and vital signs, ECG etc. performed at screening

5. Individuals who signed an informed consent form and decided to participate in the study after being fully informed of the study prior to participation

6. Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion

7. Individuals with the ability and willingness to participate the entire study period

Exclusion Criteria:

1. Individuals with a medical evidence or a history of clinically significant hepatobiliary, renal, neurologic, respiratory, digestive, endocrine, blood-oncology, urinary, cardiovascular, musculoskeletal or psychiatric

2. Individuals with a medical history of gastrointestinal disease (e.g., Crohn's disease and ulcer) or gastrectomy (excluding simple appendectomy or herniotomy) that may affect drug absorption

3. Individuals with the following results at screening test:

- ALT or AST > 2x the upper limit of the normal range

- Creatinine > upper limit of the normal range or eGFR with MDRD <60 ml/min/1.73 m2

- ECG Result, QTc > 450msec

- CPK > UNL(upper normal limit) x 3.0

- K > 5.5mEq/l

- Hct < lower limit of the normal range

4. A history of regular alcohol consumption exceeding 21 units/week within the 3 months(1 unit = 10 g = 12.5 ml) prior to screening or individuals who cannot quit drinking from 48hr prior to the first dose to end of last blooding (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)

5. Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening or cannot quit smoking during hospitalization period

6. Individuals who had been administered investigational product(s) of other clinical study or bioequivalence study within the 6 months prior to the first dose of this study

7. Following vital signs results at screening

- Sitting systolic blood pressure = 140 mmHg or < 90 mmHg

- sitting diastolic blood pressure =90 mmHg or <60 mmHg

8. Individuals with a medical history of significant drug abuse within one year prior to the screening or positive for abuse drug in urine test results at screening

9. Individuals taking medication known to significantly induce or inhibit drug metabolizing enzymes within 30days before the first administration of clinical trial drug

10. Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)

11. Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)

12. Individuals with hypersensitivity to investigational products or the investigational products ingredients

13. Patients or conditions deemed to be at risk for using investigational products

- Patient with hyperkalemia

- Patients with hepatopathy

- Patients with hereditary angioedema, ACE inhibitors or angiotensin 2 receptor antagonists who have a history of angioedema

- Primary hyperaldosteronism

- Patients with aortic valve stenosis, mitral (valve) stenosis, hypertrophic obstructive cardiomyopathy

- Patients with ischemic heart disease, ischemic cardiovascular disease, cerebrovascular disease

- Patients with Intravascular volume depletion

- Patients with diabetes or kidney failure

- Patients with renal artery stenosis

- Patients with muscle disease

- Patients with Hypothyroidism

- Patients with a history of muscle toxicity when using statins or fibrates

- Patients who have recently had a kidney transplant

- Patients with history of shock

14. Individuals with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.

15. Individuals who drunk grapefruit juice or caffeine more than 5 cup per day within 3 months prior to screening or cannot quit drinking during clinical trials period

16. Individuals who cannot eat standard meal in institution

17. Women who are pregnant or may be pregnant

18. Individuals who were deemed to be inappropriate to participate in the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CKD-330 Tab. and D086 Tab.
1T
CKD-333 Tab.
1T

Locations

Country Name City State
Korea, Republic of Jang Hee Hong Daejeon

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUCt of CKD-330, D086, CKD-333 Area under the CKD-330/D086/CKD-333 concentration in blood-time curve from zero to final [Time Frame: Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours]
Primary Cmax of CKD-330, D086, CKD-333 The maximum CKD-330/D086/CKD-333 concentration in blood sampling time t [Time Frame: Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours]
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment